Actelion pays Auxilium $10M up front for Dupuytren's, Peyronie's drug
This article was originally published in Scrip
Executive Summary
Actelion Pharmaceuticals has agreed to pay Auxilium Pharmaceuticals $10 million up front as part of a long-term deal which provides Actelion with exclusive rights to commercialise Xiaflex (collagenase Clostridium histolyticum) as a treatment for two rare progressive collagen deposit conditions, Dupuytren’s contracture and Peyronie’s disease, in Canada, Australia, Brazil and Mexico.